Skip to content

EPS (Diluted) at other companies

Avanos Medical logo
Avanos MedicalAVNS
$0.11-21.4%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$0.40+471%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s EPS (diluted)?
Pacira BioSciences, Inc. (PCRX) reported EPS (diluted) of $0.07 in Q1 2026.
How has Pacira BioSciences, Inc.'s EPS (diluted) changed year-over-year?
Pacira BioSciences, Inc.'s EPS (diluted) decreased by 30.0% year-over-year, from $0.10 to $0.07.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.